Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap
Teva Pharmaceutical Industries stock has delivered a very strong 308.6% return over the past three years, while the Discounted Cash Flow (DCF) intrinsic value estimate still flags the shares as trading at a sizeable discount of 48.4% to that model, which contrasts with market multiples that look closer to fair.
- Over three years, Teva Pharmaceutical Industries has returned 308.6%, which puts recent short term pullbacks into the context of a large prior re-rating.
- Progress in higher margin biopharmaceuticals, including vitiligo and schizophrenia programs, can support the cash flow outlook. However, any setbacks in these pipelines or biosimilar launches may weigh on what investors are willing to pay for the stock.
- On Simply Wall St's valuation checks, Teva Pharmaceutical Industries scores 4 out of 6, which points to a mixed picture rather than a clear bargain or clear overvaluation.
The issue now is whether Teva Pharmaceutical Industries still offers enough upside relative to its intrinsic value estimate after such a strong three year run, or if the recent share price better reflects its prospects.
Does Teva Pharmaceutical Industries Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model values Teva Pharmaceutical Industries by projecting its future cash generation and discounting it back to today. On this basis, Teva's latest twelve month free cash flow is about $1.17b, with the model assuming growing cash flows over time that then level off. Those projections translate into an estimated intrinsic value of about $64.20 per share in $.
Compared with the current share price, that DCF output implies Teva stock trades at roughly a 48.4% discount, which is a wide gap for a company already producing positive free cash flow. The recent progress with TEV-408 for vitiligo and the expanding biosimilars pipeline helps explain why the cash flow projections used in the model extend beyond the legacy generics base. Despite that pipeline activity providing potential support for future cash flows, the market price still sits well below what this DCF suggests.
Overall, the Discounted Cash Flow (DCF) workup indicates Teva Pharmaceutical Industries stock currently appears undervalued on this model’s assumptions.
Our Discounted Cash Flow (DCF) analysis suggests Teva Pharmaceutical Industries is undervalued by 48.4%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.
Where Does Teva Pharmaceutical Industries Sit on Earnings?
P/E is a useful way to look at Teva Pharmaceutical Industries because earnings are a key focus for investors in established pharmaceutical companies. Teva currently trades at a P/E of about 24.6x, which is higher than the pharmaceuticals industry average of roughly 15.3x and also above the peer group average of about 19.4x.
A P/E ratio of around 26.6x is estimated as a fair level based on Teva’s size, industry, margins and risk profile. This leaves the stock trading slightly below this tailored fair multiple, even though it trades at a premium to the broader industry and peers on simple averages.
Overall, Teva Pharmaceutical Industries stock appears to be priced roughly in line with what this P/E framework suggests is fair.
See what the numbers say about this price — find out in our valuation breakdown.
The Teva Pharmaceutical Industries Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Teva Pharmaceutical Industries pick up where the valuation puzzle leaves off, spelling out which paths for Teva Pharmaceutical Industries' growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price. These Narratives sit on the company’s Community page. Rather than relying on a single multiple or model, each Narrative lays out the assumptions behind its fair value so you can compare them with Teva Pharmaceutical Industries' actual results over time.
Community views on Teva Pharmaceutical Industries are far apart, with one camp seeing meaningful upside and another warning the stock could be pricing in too much.
Bull case: 19% undervalued
"Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion..."
Read the full Bull Case to see why Teva Pharmaceutical Industries could be undervalued
Bear case: 54% overvalued
"Heavy reliance on a narrow set of growth engines such as AUSTEDO, UZEDY and AJOVY, in indications where underdiagnosis and undertreatment are being actively addressed across the industry, could expose Teva to future competitive launches and reimbursement tightening that may cap pricing power and slow top line expansion, pressuring revenue growth targets..."
Read the full Bear Case to see why Teva Pharmaceutical Industries could be overvalued
Do you think there's more to the story for Teva Pharmaceutical Industries? Head over to our Community to see what others are saying!
The Bottom Line
For Teva Pharmaceutical Industries, the Discounted Cash Flow (DCF) work points to an intrinsic value well above the current share price, while the tailored P/E view suggests the stock is closer to about right. That mix, together with the broader checks scoring as mixed rather than strong, leaves the stock looking potentially undervalued but not without clear risks. The key question from here is whether Teva can translate its higher margin pipeline and biosimilar efforts into durable cash flows that justify the intrinsic value estimate, or whether competitive and execution pressures mean the current market scepticism is better aligned with reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com